Latest News

  • Alkermes Statement on National Academies of Sciences, Engineering, and Medicine Report on Medications for Opioid Use Disorder Read More
  • Alkermes' Corporate Presentation to be Webcast at the Cowen and Company 39th Annual Health Care Conference Read More
  • Alkermes Initiates Clinical Study of ALKS 4230 Administered Subcutaneously in Patients With Advanced Solid Tumors Read More

Investors

Working at Alkermes